Fellowship · New Haven, CT
Sponsored by Yale-New Haven Hospital
Tirzepatide Once Weekly for the Treatment of Obesity.
The New England journal of medicine · 2022 · 2,783 citations · Ania Jastreboff
Triple-Hormone-Receptor Agonist Retatrutide for Obesity - A Phase 2 Trial.
The New England journal of medicine · 2023 · 858 citations · Ania Jastreboff
Tirzepatide for Obesity Treatment and Diabetes Prevention.
The New England journal of medicine · 2025 · 338 citations · Ania Jastreboff
Continuous glucose monitoring and metrics for clinical trials: an international consensus statement.
The lancet. Diabetes & endocrinology · 2023 · 684 citations · Stuart Weinzimer
Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial.
Lancet (London, England) · 2023 · 644 citations · Ania Jastreboff
American Association of Clinical Endocrinology Clinical Practice Guideline for the Diagnosis and Management of Nonalcoholic Fatty Liver Disease in Primary Care and Endocrinology Clinical Settings: Co-Sponsored by the American Association for the Study of Liver Diseases (AASLD).
Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists · 2022 · 806 citations ·
Consensus Recommendations for the Use of Automated Insulin Delivery Technologies in Clinical Practice.
Endocrine reviews · 2023 · 334 citations · Jennifer Sherr, Stuart Weinzimer
A Glycemia Risk Index (GRI) of Hypoglycemia and Hyperglycemia for Continuous Glucose Monitoring Validated by Clinician Ratings.
Journal of diabetes science and technology · 2023 · 237 citations · Jennifer Sherr